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Hepatocellular carcinoma (HCC) is a highly aggressive malignancy. Nanosecond pulsed electric ﬁeld
(nsPEF) is a new technology destroying tumor cells with a non-thermal high voltage electric ﬁeld using
ultra-short pulses. The study’s aim was to evaluate the ablation efﬁcacy of nsPEFs with human HCC cell
lines and a highly metastatic potential HCC xenograft model on BALB/c nude mice. The in vivo study
showed nsPEFs induced HCC cell death in a dose dependent manner. On the high metastatic hepatocel-
lular carcinoma cell line (HCCLM3) xenograft mice model, tumor growth was inhibited signiﬁcantly in
nsPEF-treated- groups (single dose and multi-fractionated dose). Besides a local effect, the nsPEF treat-
ment reduced pulmonary metastases. The nsPEFs also enhanced HCC cell phagocytosis by human mac-
rophage cell (THP1) in vitro. The nsPEF is efﬁcient in controlling HCC progression and reducing its
metastasis. NsPEF treatment may elicit a host immune response against tumor cells. This study suggests
nsPEF therapy could be used as a potential locoregional therapy for hepatocellular carcinoma.
 2014 The Authors. Published by Elsevier Ireland Ltd.Open access under CC BY-NC-ND license.1. Introduction When surgical options cannot be achieved, locoregional therapiesHepatocellular carcinoma (HCC) is one of the most lethal can-
cers in the world [1,2]. Radical resection is the ﬁrst line of treat-
ment but in clinical practice surgery is not often feasible because
of an unresectable size or underlying liver cirrhosis. Liver trans-
plantation is curative treatment but limited by organ shortage.including radiofrequency ablation (RFA), percutaneous ethanol
injection (PEI) and transarterial chemoembolization, are recog-
nized as appropriate choices and are radical treatments choices
for selected patients [3–5].
Nanosecond pulsed electric ﬁeld (nsPEF) is an emerging bioelec-
trical technology that has showed its potential in cancer therapy
[5,6]. NsPEF can generate pulsed high voltage electric ﬁeld in ultra
short nanosecond duration to produce immediate power, which
could ablate targeted tumor [7–9]. NsPEF mediates cell destruction
by multiple mechanisms [5]. The nanosecond pulses with a high
intensity electric ﬁeld changes the permeability and electric prop-
erties of the plasma membrane and intracellular organelle mem-
brane, which eventually result in apoptosis or apoptosis-like cell
death. Unlike RFA or PEI, nsPEFs does not rely on heat production
or chemical ablation, thus producing a lower risk of local complica-
tions, such as thermal or chemical injuries [5,6]. Moreover, nsPEFs
can obliterate tumor capillaries with no concurrent impact on
larger vessels with thick walls in the targeted area [10]. So nsPEFs
can be safely delivered near a large bile duct or vascular vessel [5].
In previous studies, nsPEF has been tested in various malignant
Fig. 1. Schematic diagram of experimental setup for nsPEF on HCC tumors
implanted on nude mice.
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cell carcinoma [15], hepatocellular carcinoma [16], cutaneous pap-
illoma and squamous cell carcinoma [17].
For nsPEF application in HCC, the following questions need fur-
ther investigation for the future clinical use. First, the parameters
of nsPEF need to be optimized because the treatment effects are
highly dependent on duration, intensity and distribution of electric
ﬁeld, dielectric constant and conductivity [4,5,9]. Second, a consid-
erable proportion of HCC cases are in the late stage. These tumors
need locoregional treatment to downstage tumor for future surgi-
cal resection. Therefore, the ablation strategy, including electrode
design, as well as spatial and temporal dose distribution, may be
critical for nsPEF treatment of HCC.
This study investigated the use of nsPEF on a human HCC cell
lines and a high pulmonary metastatic potential HCC xenograft
model using on BALB/c nude mice. We demonstrated nsPEF treat-
ment, in both single and multiple fractionated dosage modes,
inhibited HCC tumors and metastases. nsPEF can also enhanced
phagocytosis of HCC cells by mononuclear cell in vitro, which sug-
gests the involvement of the host’s immune system in nsPEF cancer
treatment.
2. Materials and methods
2.1. Cells and animals
Human hepatocellular carcinoma cell line SMMC7721 and macrophage cell line
THP1 were purchased from the Chinese Academy of Science. High metastatic HCC
cell line HCCLM3 was purchased from the Liver Cancer Institute, Zhongshan Hospi-
tal, Fudan University. HCCLM3 and SMMC7721 cells were grown in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing 10% FBS, penicillin (100 units/mL),
and streptomycin (0.1 mg/mL). THP1 cells alone and the co-culture of THP1 with
SMMC7721 cells in 1640medium with 10% FBS. All cells were incubated at 37 C
in a humidiﬁed incubator under an atmosphere of 5% CO2/95% air.
BALB/c nude mice were purchased from Shanghai Experimental Animal Centre,
Chinese Academy of Science. All studies on mice were conducted in accordance
with the Guide for the Care and Use of Laboratory Animal of Zhejiang University.
PKH67 Green Fluorescent Cell Linker Kit for General Cell Membrane Labeling
(PKH67GL-1KT) and PKH26 Red Fluorescent Cell Linker Kit for General Cell Mem-
brane Labeling (PKH26GL-1KT) were purchased from Sigma, U.S.A.
2.2. Pulse generator and nsPEF parameters
A pulser with Blumlein line conﬁguration generated 100 ns pulses. Pulses were
applied at 40 kV/cm with a rate of 0.5 Hz. The application electrodes, pulse gener-
ator, voltage and pulsing pattern of the nsPEF were described previously [18]. The





whereW is the energy (J), s is the pulse duration (ns), V is the voltage across the elec-
trodes (V), R is the tissue resistance (X), and N is the pulse number. The dose effect
was studied by varying the pulse numbers while keep other parameters constant.
2.3. Electrode design for tumor ablation experiments
The nsPEF were delivered to subcutaneous tumors with a pair of electrodes
where the anode was placed within the tumor mass and the cathode was placed
on the tumor periphery (Fig. 1). The anode was a needle and the cathode was a
semi-ring. A semicircular-shaped of electric ﬁled was formed between the two elec-
trodes. One half of the tumor was treated with the initial semi-circular ring place-
ment and then the ring was rotated 180 to complete the tumor treatment. Thus the
semi-circular ring touched the tumor securely avoiding electrical breakdown.
2.4. Tumor implantation and tumor volume measurement
A pulmonary metastatic human HCC animal model was established by implant-
ing tumor tissue subcutaneously into nude mice as previously described [19,20].
Brieﬂy, suspended HCCLM3 cells were injected into the nude mouse to form a pri-
mary tumor. Once formed the primary tumors was excised and cut into cubic blocks
about 1 mm3 to be transplanted subcutaneously into 3-week old nude mice. Four
weeks after implantation, tumors were visible at 5 mm in diameter. Mice were
anesthetized on a warming bed during each procedure by inhalation anesthesia
using 1.4% isoﬂurane mixed in 100% O2. Before and after the treatment, tumorswere measured and imaged by photography. Tumor volumes were calculated using
the following formula: V = 0.52  D1  D1  D2 (D1 and D2 are short and long tumor
diameter respectively). The relative tumor volume was calculated as (tumor volume
post-treatment/tumor volume pre-treatment)  100%.2.5. Experimental group and nsPEF treatment
On day 21 after birth BALB/c nude mice were implanted with HCCLM3 tumor
blocks. Twenty seven mice were randomly divided into four groups to deliver the
ﬁrst treatment on day 49: 7 mice in control group, in which mice were anesthetized
and the electrode was placed on the tumor, but no nsPEF was applied; 6 mice in the
surgical resection group, in which the whole subcutaneous tumors were resected; 7
mice in the single dose nsPEF group (nsPEF-SD), in which tumors were treated with
a nsPEF of 40 kV/cm amplitude, 100 ns ns duration for 300 pulses in a single treat-
ment; 7 mice in the multiple fractionated dose group (nsPEF-MFD), in which tu-
mors were treated with nsPEFs of 40 kV/cm amplitude, 100 ns duration for 100
pulses over three-dose regimen at 48 h intervals. Mice in this group had the second
and the third treatment while the other two groups had only anesthesia. The tumor
volume was measured in every 3 days. If tumor volume exceeded 2 cm3, the mouse
was euthanized.2.6. Histology and immunohistochemistry of tissue section
The subcutaneous tumor, lung, bowel, liver, brain, heart, spleen and kidney
were excised, ﬁxed in 4% formaldehyde dehydrated, cleared and then embedded
in parafﬁn blocks to cut into 4 lm sections for H&E staining and immunohisto-
chemistry. The expression of CEA, PCNA, CK19 and CK18 was detected by an immu-
nohistochemical assay. Brieﬂy, the endogenous peroxidase activity of sections was
inactivated with H2O2. The sections were ﬁrst incubated with the rabbit anti-hu-
man primary antibodies against CEA (Sigma 1:100), PCNA (Abcam 1:1000), CK18
(Abcam 1:100) and CK19 (Abcam 1:250), and then the secondary antibodies of bio-
tinylated goat anti-rabbit IgG (Boster, China) and avidin-biotin-peroxidase complex
(Boster, China). After staining with diaminobenzidene (DAB), sections were ob-
served under a light microscope. The results were evaluated by two independent
pathologists.2.7. Cell survival analysis after nsPEFs
Cells were harvested and 1  106 cells were placed in 0.2 cm gap cuvettes (Bio-
smith, Biorad) and exposed to nsPEF with 100 ns duration and 40 kV/cm amplitude.
After 24 h, these cells were counted with a CCK8 Cell Counting Kit (Merck-Milli-
pore) and the surviving number counted with Biotekmicroplate reader at OD450.
The relative cell survival was calculated as (OD450 treated cell/OD450 control
cell)  100%.2.8. Phagocytosis with the confocal ﬂuorescent microscopy
An in vitro co-culture system was developed to investigate the phagocytosis.
THP-1 cells (0.2  105 cells/well) were differentiated into macrophages in 24-well
plate containing 1 mL medium/well with phorbol ester (80 ng, PMA, Sigma USA)
over 72 h. After incubation for 72 h, the cells were washed twice with the medium
and incubated with a human HCC cell line SMCC7721 in a 1:1 ratio with total num-
ber of 1  106 cells. SMMC7721 were labeled with a red ﬂuorescent dye (PKH26)
and THP1 with a green ﬂuorescent dye (PKH67).
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HCCLM3 cells or co-cultured SMMC7721 cells and THP1 cells were processed
according to the standard technical procedure for transmission electron micros-
copy. Cell microstructure was observed on a JEM-1200EX electron microscope.2.10. Statistical analysis
Statistical analysis was performed with SPSS 15.0 for windows (SPSS, Chicago,
IL, USA). Quantitative variables were expressed as means ± SD and analyzed by AN-
OVA. Survival difference was evaluated by the log-rank test and the Kaplan–Meier
method. Results were considered statistically signiﬁcant at P < 0.05.3. Results
3.1. Nanosecond PEF ablation effectively induced HCC cell death in a
dose dependent manner in vitro
We ﬁrst examined the effect of nsPEFs at varied dose on
HCCLM3 HCC cells. The nsPEFs were supplied by a nanosecond
pulse generator and delivered to HCC cells in cuvettes, as previ-
ously described by Wang et al. [18]. The morphological changes
of treated HCC cells were observed by TEM. When HCCLM3 cells
were pulsed with 30 pulses of nsPEFs, they showed apoptosis-like
characteristics including nuclear condensation, oversized cytoplas-
mic particles with integral cellular membranes and organelles
(Fig. 2A). Twenty-four hours after treatment, the cell survival
was determined by CCK-8 assay and nsPEFs produced dramatically
decreasing in vitro cell survival when the pulse number exceeded
20 (Fig. 2B). When the pulse number exceeded 100 in vivo
(Fig. 1), the histological analysis showed cellular destruction
throughout the tumor (Fig. 2C).Fig. 2. nsPEF effectively induced HCC cell death in vivo and in vitro. (A) Morpho-
logical changes of HCC-LM3 cells treated with 0 pulse, 10 pulses, 20 pulses and 30
pulses of 40 kV/cm amplitude 100 ns duration PEF. (B) Relative cell survival was
evaluated by CCK-8 at 24 h after 10, 20, 30, 40, 50, 60, 70, 80 and 90 pulses of 40 kV/
cm 100 ns nsPEF treatment. (C) Histological analysis of tumors formed by HCC-LM3
cells on nude mice with or without 100 pulses of 40 kV/cm 100 ns PEF. A large area
of cell death is seen in the treated tumor compared to the untreated tumor.
Magniﬁcation: 40 for original image and 100 for views in left upper corners.3.2. NsPEFs suppressed tumor growth of subcutaneous implanted
human HCC in the mouse model
The effect of nsPEFs on murine hepatoma has been reported
[16]. Here we have developed an nsPEF ablation model for human
HCC xenograft in nude mice. HCCLM3 tumor blocks were im-
planted in mice. An nsPEF treatment was started when the tumor
had an average volume of 400 mm3 four weeks post implantation.
Two experimental pulsing parameters were used: (1) a single dose
ablation (nsPEF-SD) group of HCC tumors were treated with 300
pulses of the nsPEF one time; (2) a multi-fractionated dose
(nsPEF-MFD) group of HCC tumors were treated with 100 pulses
of the nsPEF for 3 times at of 48 h intervals. Control group mice
were anesthetized but without nsPEF treatment. After treatment,
the tumor volumes were measured. If the tumor volume exceeded
2 cm3, that mice was euthanized. As shown in Fig. 3A, nsPEF-
treated tumors regressed. On post treatment days 7 and 14, tumor
growth in nsPEF-SD and nsPEF-MFD groups was signiﬁcantly
inhibited compared to the control group (P < 0.01, Fig. 3B). There
were no complications caused by nsPEF treatment and no signiﬁ-
cant mouse weight loss post-nsPEF treatment.
The survival of the mice was followed the 11th week. The end-
point was deﬁned as tumor volume exceeding 2 cm3. Kaplan–
Meier survival curve is shown in Fig. 3C. The mean post-treatment
survival was 23.1 days (range, 15–33 days) in the control group,
38.1 days (range, 21–52 days) in the nsPEF-SD group and 49.7 days
(range, 36–52 days) in the nsPEF-MFD group. The survival time of
both nsPEF treatment groups was signiﬁcantly longer than that of
the control group (P < 0.05).
Thus experiment is capable of inhibiting tumor growth, reduc-
ing tumor burden and prolonging animal survival. No severe ad-
verse effect was found in the nsPEF-treated groups.3.3. nsPEF treatment reduced pulmonary metastasis of HCC
To investigate whether nsPEF cause tumor seeding, we further
examined lung metastases from HCCLM3 xenograft in nude mice.
HCCLM3 is a human hepatocellular carcinoma cell line with high
metastatic potential, which was established from a human HCC
metastatic tumor. HCCLM3 produces lung metastases when im-
planted subcutaneously in BALB/c nude mice [19,20]. In our exam-
ination, metastatic nodules were found in the control group, the
nsPEF-SD group and resection group as shown in Fig. 4A. The
Fig. 3. nsPEFs suppressed tumor growth of subcutaneously implanted human HCC
on mice model. Photographs of HCC xenograft tumors in control, nsPEF-SD and
nsPEF-MFD group on day 14 after treatment. Tumors treated by single dose of nsPEF
and multiple fractionated dose of nsPEF decreased in volume, while tumors in the
control group continued growing. (B) Relative volume changes of HCC xenograft
tumors in control, nsPEF-SD and nsPEF-MFD group. Both nsPEF treated groups
showed decrease in relative tumor volume compared to control (p < 0.05). (C)
Kaplan–Meier survival curve for mice in control, nsPEF-SD and nsPEF-MFD group.
The mean post-treatment survival was 23.1 days (range, 15–33 days) for the control
group, 38.1 days (range, 21–52 days) for the nsPEF-SD group and 49.7 days (range,
36–52 days) for the nsPEF-MFD group. NsPEF-SD and nsPEF-MFD group showed
prolonged survival as compared with the control group (p < 0.05).
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were expressing CK18 [21], CK19 [22,23], CEA [24] and PCNA
[25], which is consistent with the expression pattern of the
HCCLM3 cell line (Fig. 4B).
CK19 (keratin 19) is generally considered the marker of intrahe-
patic bile duct cells or hepatic progenitor cell. CK19 in HCC is usu-
ally associated with recurrence, metastasis and poor prognosis
[22,23]. CK 19 is also a potential marker of circulating tumor cells.
CK18 is the marker of liver parenchymal cells and hepatoma cells
express CK18 [21]. Proliferating cell nuclear antigen (PCNA) is a
key factor for DNA replication and cell cycle regulation. PCNA is
usually expressed in the cells with fast growth and proliferation
[25]. Carcinoembryonic antigen (CEA) is expressed in related
malignant cells such as metastatic colorectal cancer related [24].
The immunohistochemical results show that implanted subcuta-
neous tumor expressed CK18, CK19, CEA and PCNA, the same
markers which HCCLM3 cells express before inoculation (Fig. 4).
The strong positive expression of CK19 in lung metastatic nodulesveriﬁed the origin of the lung metastases to be from the subcuta-
neously-implanted HCCLM3 cells.
The number of animal with lung metastases was 7 of 7 animals
in the control group, 2 of 7 in the nsPEF-SD group, 0 of 7 in the
nsPEF-MFD group and 1 of 6 in the resected surgery group, respec-
tively (Fig. 4C). Mice with a single dose of nsPEF ablation showed
reduction in the lung metastases rate compared to the control
group, and the nsPEF-MFD treatment achieved a metastatic rate
as low as resection group. It showed nsPEF decrease lung metasta-
sis from the primary tumor.3.4. nsPEF enhanced phagocytosis of HCC cells by macrophage cell
in vitro
Locoregional therapy like radiofrequency ablation can elicit
speciﬁc or non-speciﬁc immune response against tumor by various
mechanisms. By histological analysis of the HCC xenograft tumor
treated by nsPEFs, we found more anti-phagocyte positive cells
present in tumor capsule, which suggested a possible role of host
defense against tumor cells (Fig. 5A and B).
We designed an experiment to observe whether nsPEF treat-
ment increases HCC cells phagocytosis by immune cells in vitro.
The HCC cell line SMMC7721 was used in this experiment since
it is optimal for a phagocytosis study and ﬂow cytometry analysis.
As shown in Fig. 2B, 40 kV/cm amplitude of 100 ns duration PEFs
with less than 20 pulses was not lethal to HCC cells in vitro. When
SMMC7721 cells were treated with 18 pulses and then co-cultured
with the macrophage cell line THP1 cell line [31]. Phagocytosis was
seen with transmission electron microscope within 4 h (Fig. 5C). In
the control group the phagocytized HCC cells were found only after
6 h post-treatment To conﬁrm the result, we performed a cell
tracking assay by labeling HCC cells (SMMC7721) with red ﬂuores-
cent dye PKH26 and THP1 cells with green ﬂuorescent dye PKH67
[32,33].
After 4 h following 18 pulses of 40 kV/cm at 100 ns, SMMC7721
[34] cells with red ﬂuorescence were engulfed by THP1 cell with
green ﬂuorescence (Fig. 5D). In ﬂow cytometry, the G region
(marked in plots) represented cells with dual ﬂuorescence. A red
stained SMMC7721 cell phagocytized by green stained THP1 cell.
When co-cultured for 4 h, a signiﬁcant greater proportion of dual
labeled cells in the G region were detected in the nsPEF-treated
group (23.00 ± 7.35%) than the control group (6.04 ± 0.73%)
(Fig. 5E and F). Thus nsPEF treatment increased the phagocytosis
of SMMC7721 HCC cells by THP1 macrophage cells.4. Discussion
The management of patients with HCC usually requires a mul-
tidisciplinary team to make a treatment plan according to the pa-
tient’s tumor characteristics and liver function. Surgical resection
and liver transplantation have been considered as curative therapy
[1,2], but surgical treatments are limited by poor liver function or
organ availability. Locoregional therapies, including direct tumor
ablation techniques and transcatheter chemoembolization, play
an important role in the non-surgical management of HCC. The
RFA therapy, one of the local ablation treatment, has been recog-
nized as comparably effective as surgical resetion for small sized
HCC [3,4].
NsPEF ablates tumor cells by non-thermal and non-chemical
effects. Different from conventional ablation techniques, nsPEF
does not result in direct necrosis in targeted tissue but induces
cell death in an apoptosis or apoptosis-like pathway [5–8,26].
Ultra-short pulsed high voltage electric ﬁeld affects plasma
membranes and membranes of intracellular organelles, which
disrupt cellular physiological homeostasis and eventually causes
Fig. 4. Lung metastases examined in HCCLM3 implanted nude mice. (A) Metastatic nodule found in the lung of a control mouse, nsPEF-SD mouse and a resectioned mouse,
while no metastases were found in nsPEF-MFD mice. (B) Immunohistochemical staining of the HCCLM3 cell line cells and representative pulmonary metastases in mouse
model (HCCLM3 cells immunostaining was shown in the upper left corner of the images of tumor tissues). The staining pattern of CEA, PCNA, CK18 and CK19 in metastatic
nodules was in consistent with cells of the HCCLM3 cell line cells. (C) Number of nude mice with pulmonary metastases in control, nsPEF-SD, nsPEF-MFD and resection group.
Compared with control group, nsPEF-SD group and nsPEF-MFD group had signiﬁcantly reduced lung metastases.
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ted by a lethal nsPEF dose in vitro did not show necrotic mor-
phological changes. In consistence, HCC tumor ablated by
nsPEFs underwent gradual shrinkage with minimal bleeding or
necrosis. The target area of nsPEFs can be strictly conﬁned by
a precisely designed electrode. The vessels with different con-
ductivity such as bile ducts, thick blood vessels or the urethra
in the treated area can be preserved [5]. When the nsPEF dura-
tion is shorter and the energy carried by single pulse is lower,
the energy release is more controllable. These features facilitate
nsPEF treatment in HCC: oversized tumors can be safely ablated
by multiple doses of nsPEF. The tumors near major vascular ves-
sels which are hard to be ablated by conventional heat produc-
ing techniques can be ablated by nsPEFs. In this study, we
compared the efﬁcacy of nsPEFs in single dose and multiple frac-
tionated doses on subcutaneous implanted HCC tumors. The re-
sult showed multiple fractionated dose nsPEFs inhibited tumors
more effectively than that with a single treatment. Therefore,
nsPEFs can be used multiple times as a downstage treatment,
especially for large tumors that are unresponsive to a single
nsPEF dose.
Beside the local ablation effect, nsPEF’s usefulness for metasta-
ses was also studied. A highly metastatic HCC xenograft model was
set up. This model showed that the multi-fractionated dose grouphad no pulmonary metastasis (0 for 7) which was even better than
the rate of metastasis in the surgical resection group (1 of 6). The
risk of metastasis can be minimized by the efﬁcient ablation of
the primary tumor.
Local treatment of a tumor can induce an immune response
[35–39]; radiotherapy can induce a tumor-speciﬁc CD8+ T cell
response [39–41] and then cause a by-stander effect. In our
study, we found the non-lethal nsPEFs greatly increases the ratio
of HCC cells engulfed by the macrophage cell THP1. Thus nsPEF
stimulate macrophages to engulf tumor cells. The multiple dose
strategy of nsPEFs extended the treatment period and it pro-
longed the duration to induce a host defense against the tumor
cells. The mechanism of this phenomenon needs further investi-
gation. Electric ﬁeld induced phosphatidyl serine (PS) external-
ization on cell membrane [26], which had been reported to be
a vital signal to immune cells [27], such as macrophages [28],
neutrophils [29] and dendritic cells [30] and this PS ﬂip could
signal the phagocytic clearance of target cells [27–30]. PS exter-
nalization was recognized as an early event that occurs in cells
undergoing apoptosis. The low dose nsPEFs merely changed cell’s
membrane permeability and rearranged PS distribution without
initiating an apoptosis cascade. Therefore, the immune system
may identify nsPEF-treated cells by the externalized PS on the
cell membrane. The recognition and phagocytosis of tumor cells
Fig. 5. nsPEF treatment enhanced phagocytosis of HCC cells by mononuclear cells in vitro. An IHC analysis found increased anti-macrophage staining positive cells in the
capsule of tumor treated by nsPEFs. (B) Quantization of anti-macrophage positive staining cells in the tumor capsule of control and nsPEF treatment groups at day 1 after
nsPEF treatment. (C) Transmission electron microscopy showed phagocytosis of a nsPEF- treated SMMC7721 cell by a THP1 cell after 4 h of co-culture. (D) Laser confocal
microscopy showed an nsPEF-treated SMMC7721 cells labeled by red PHK26 was phagocytized by THP1 cells labeled by green PKH 67 after co-culture. (E) Flow cytometry
analysis of co-cultured SMMC7721 and THP1 cells with or without nsPEF treatment. G region represents dual ﬂuorescent cells with both PHK 26 and PKH 67 labeling, which
indicated phagocytosis of SMMC-7721 HCC cell by THP1 cell. After nsPEF treatment, dual ﬂuorescent cells undergoing phagocytosis increased compared with control. (F)
Quantitation of dual ﬂuorescent cells in ﬂow cytometry analysis of control and nsPEF-treated SMMC-7721 cells co-cultured with THP1 cells.
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immunological reaction and tolerance within tumor [42–44].
The nsPEF-stimulated engulfment of tumor cells may or may
not be the trigger for a tumor-antigen speciﬁc immune re-
sponses [45] or tumor-speciﬁc CTL [46]. However our study sug-
gests that nsPEFs induce tumor eradication by an immune
response with an unlethal dosage.
In conclusion, our study showed the nsPEF treatment is an efﬁ-
cient means to control HCC growth in an animal model. The multi-
ple fractionated dose of nsPEFs efﬁciently inhibited tumors
without increasing the risk of secondary metastasis. Beyond a local
ablation effect, the nsPEF also elicit tumor cell removal by a host
defense. Therefore, nsPEF can be used as a locoregional therapy
for hepatocellular carcinoma.Conﬂict of Interest
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